Study of Chimeric Fibril-Reactive Monoclonal Antibody 11-1F4 in Patients With AL Amyloidosis | oneAMYLOIDOSISvoice
terminado

Study of Chimeric Fibril-Reactive Monoclonal Antibody 11-1F4 in Patients With AL Amyloidosis

información clave

ID de estudio #: NCT02245867

condición: Amilosis

Estado: Completado

propósito:

The purpose of this study is to examine the tolerance, safety, pharmakinetics, and possible clinical benefit of the good manufacturing practice (GMP)-grade amyloid fibril-reactive chimeric (Ch) IgG1 mAb 11-1F4 in patients with amyloid light-chain (AL) amyloidosis.

The phase 1a part will involve at least 3 patients and a maximum of 18 patients. The first patient will receive the starting dose of the antibody and, if tolerated, the following patients will each receive (if tolerated) progressively higher doses of the antibody. Patients in part 1a of the trial will receive only one infusion of the drug. Patients treated in the phase 1a part receive lower dosage which might not be effective.

Once the maximal tolerated dosage is established during the phase 1a part, the investigators will accrue patients to the phase 1b part of the trial. Patients will receive 4 infusions, once each week for 4 weeks. Patients who were treated in the part 1a of the trial and showed no toxicity can be also treated in the part 1b of the trial. The first patient will receive the starting dose of the antibody and, if tolerated, the following patients will each receive (if tolerated) progressively higher doses of the antibody. When the investigators reach the maximum tolerated dose without toxicity, the investigators e will enroll another 4 patients to receive the same dose. If there are no toxicities, another 4 patients will be treated at the next dose level, and so forth. Patients treated in Phase 1b may receive lower dosages which might not be effective. The goal of Phase 1b is to establish the tolerance and possible beneficial effects of 11-1F4. If successful, treatment with this antibody would represent a novel approach in the care of individuals with AL amyloidosis.

intervención: Chimeric Fibril-Reactive Monoclonal Anti-body 11-1F4

Resultados: https://clinicaltrials.gov/ct2/show/results/NCT02245867

última actualización: 17 de Septiembre de 2021

Para mejorar su experiencia en este sitio, utilizamos cookies. Esto incluye cookies esenciales para el funcionamiento básico de nuestro sitio web, cookies con fines analíticos y cookies que nos permiten personalizar el contenido del sitio. Al hacer clic en 'Aceptar' o en cualquier contenido de este sitio, acepta que se puedan colocar cookies. Puede ajustar la configuración de cookies de su navegador para adaptarla a sus preferencias.
Más información

La configuración de cookies en este sitio web se establece en "permitir cookies" para darle la mejor experiencia de navegación posible. Si usted continúa utilizando este sitio web sin cambiar la configuración de cookies o hacer clic en "Aceptar" El consentimiento de abajo y usted tiene que esto.

Cerrar